Get In Touch

As per a report of International Journal of Reproduction, approximately 15% of couples are reportedly suffering from infertility. This implies that 60–80 million couples experience certain reproduction complexity annually.

Late child planning, smoking, alcohol and drug abuse, and sedentary lifestyle are some of the significant risk factors. These risk factors are anticipated to increase infertility incidence in forthcoming years. As a result, demand for assisted reproductive technologies is anticipated to accelerate. This, in turn, will explicitly boost growth of human reproductive technologies market.

Rising awareness about assisted reproductive technology is one of the key factors driving growth in human reproductive technologies market. In various countries, medical associations are undertaking initiatives and implementing programs to raise awareness about infertility and related treatment.

For example, ASPIRE is an initiative on reproduction in Asia Pacific region. It aims to provide knowledge regarding human reproductive technologies throughout the region.

Such initiatives along with rising infertility rate are projected to fuel adoption rate of human technologies in coming years.

Expansion of healthcare infrastructure and availability of specialized treatment are major factors contributing to growth of the global human reproduction technologies. For example, in 2014, 77,721 human reproduction technology-based treatment procedures were performed in Australia and New Zealand.

For specialized treatment and proper attention of medical practitioner, people are opting clinics for infertility treatment. Hence, clinic segment is projected to contribute to growth of human reproduction technologies market in forthcoming years.

Meanwhile, high cost of treatment is estimated to interfere with the growth rate of human reproductive technologies market in several regions, especially in emerging economies. In addition, social and ethical concerns in developing countries may restrain adoption rate of human reproductive technologies.

Human reproductive technologies include procedures and therapies for conceiving or controlling pregnancy by means of artificial and/or semi artificial medical solutions. Reproductive technologies are used to treat infertility problems in males as well as in females. Since the last decade, a remarkable prevalence of infertility has been observed worldwide and its morbidity rate is rapidly growing. Changes in lifestyle such as delay in bearing the first child, use of contraceptive pills, increased alcohol consumption and smoking are some of the factors leading to increase in the infertility rate globally, due to which the human reproductive technologies market is experiencing rise in demand. The World Health Organization (WHO) reported that in 2010, approximately 1.9% of women aged between 20 years and 44 years were unable to have their first child and 10.5% of women who had already conceived were unable to conceive for the subsequent times. Thus, high global infertility rates will continue to provide newer growth opportunities to this market. Some other factors contributing to the growth of the human reproductive technologies market include increasing morbidity rate of infertility in both males and females, rise in awareness about the available technologies for treating problems related to reproduction, rising prevalence of unwanted pregnancies, and overall advancement in the available technologies to control reproduction.  
Human reproductive technologies are mainly categorized on the basis of infertility treatments and contraceptive technologies. The infertility drugs market is analyzed based on the big seven brands (by sales) such as, Gonal-f, Follistim AQ, AndroGel, Testim, Viagra, Cialis and Levitra/Staxyn. Viagra, Gonal-f and AndroGel are the major drugs in their respective drug classes, which are preferred majorly for treating different causes of infertility. Further, the human reproductive technologies market is analyzed by various infertility treatment procedures which is led by the intrauterine insemination (IUI) procedure owing to low procedural cost and less complexity in performing the procedure. 
Contraceptive technologies market is segmented into contraceptive drugs such as oral contraceptive pills, contraceptive injectables and topical contraceptives; and devices such as male and female contraceptive devices. Within the contraceptives market, the market share of male contraceptives was the largest due to factors such as ease of use, lack of side effects and higher availability. The market will be driven by factors such as increase in conception rate, rising prevalence of unwanted pregnancies and sexually transmitted diseases (STDs).
The global human reproductive technologies market is highly fragmented in nature with many companies currently competing in the market. Well established market players such as Merck & Co., Inc., Ferring International Center S.A., Pfizer, Inc. Merck Serono and Bayer AG dominate this market with their proprietary products and predatory growth strategies. Patent repositories of the established market players are restraining the entry and growth of new players entering the market. 
Geographically, North America dominates the global human reproductive technologies market and is followed by Europe. Important factors that have led to rise in infertility incidence in North America include high obesity rates, rising age of conception and hazards emerging from shift in lifestyle. Women become less fertile at around 30 years of age and this rate speeds up after 35 years of age. Asia-Pacific is expected to show the highest growth rate in the human reproductive technologies market owing to factors such as highest population in the world, increasing awareness about reproductive technologies and increasing disposable income of the population in this region. One of the major issues restraining the market in emerging economies is the lack of initiatives to consult a specialist for reproductive disorders. However, rapid adoption of western lifestyle and rising incidence of hypertension is affecting the ability to conceive and thus, driving the demand for infertility drugs and devices in this region.

Human reproductive technologies encompass therapies and procedures for conceiving and controlling pregnancy by artificial and semi-artificial means. The popularity of reproductive technology has increased tremendously in the last couple of years, especially in the treatment of infertility in men and women alike. Incidence of infertility among women grew significantly in the last decade owing to delay in conceiving the first child, alcohol abuse, smoking addiction, and use of contraceptive pill. This in turn has spurred the human reproductive technologies market globally. 

In order to provide an in-depth analysis, the report segments the global reproductive technologies market on the basis of infertility drugs, procedures, and contraceptive technologies. Key geographic regions covered by the report are North America, Europe, Asia Pacific, and Rest of the World. 

The report provides an executive-level blueprint of the global human reproductive technologies market. The parameters shaping the present market dynamics are studied in detail, while refined growth forecasts are made based on information sourced through primary and secondary research. To present a 360-degree overview of the global reproductive technologies market, the report evaluates the growth drivers, threats, and potential growth opportunities impacting its development. 

Overview of the human reproductive technologies market

The World Health Organization (WHO) reported in 2010 that almost 1.9% of the global female population between the age of 20 years and 44 years were unable to conceive their first child, while 10.9% of the women who had already given birth to a child faced problems conceiving the subsequent time. The globally increasing prevalence of infertility will propel the global human reproductive technologies market substantially. 

Based on geography, the global human reproductive technologies market can be segmented into North America, Europe, Asia Pacific, and Rest of the World (RoW). Among the key geographic segments, North America dominates the market, followed by Europe. High incidence of obesity, paradigm shift in lifestyle choices, and increasing age of conception are key factors driving the human reproductive technologies market in North America. 

The report identifies Asia Pacific as the fastest growing market for human reproductive technologies. Rapidly increasing population and disposable income together with growing awareness about results achieved from reproductive technologies in Asia Pacific will give a remarkable boost to the human reproductive technologies market in the region. However, inadequacy of initiative to consult a specialist for infertility issues among a significant portion of the population in Asia Pacific will emerge as a major roadblock for the market in this region. 

Nevertheless, increasing adoption of the Western lifestyle and growing prevalence of hypertension in the region will adversely affect the ability to conceive among women in Asia Pacific, which is expected to give the human reproductive technologies market in Asia Pacific an incredible impetus. 

Companies mentioned in the research report 

Prominent players profiled in the report include Boston Scientific Corporation, Bayer Healthcare AG, Ferring International Center S.A., Church & Dwight, Co. Inc., Merck KGaA, and Teva Pharmaceutical Industries, Ltd.

Human Reproductive Technologies Market by Infertility Drugs

  • Gonal-f (recombinant follitropin alfa)
  • Follistim AQ (follitropin beta)
  • AndroGel (testosterone)
  • Testim (testosterone)
  • Viagra (sildenafil citrate)
  • Cialis (tadalafil)
  • Levitra/Staxyn (vardenafil)

Human Reproductive Technologies Market, by Infertility Procedures

  • In Vitro Fertilization (IVF)
  • Intracytoplasmic Sperm Injection (ICSI)
  • Zygote Intrafallopian Transfer (ZIFT)
  • Gamete Intrafallopian Transfer (GIFT)
  • Intrauterine Insemination (IUI)

Human Reproductive Technologies Market, by Contraceptive Technologies

  • Drugs
  • Oral Contraceptive Pills
  • Contraceptive Injectables
  • Topical Contraceptives


  • Male Contraceptive Devices (Male Condoms)
  • Female Contraceptive Devices

Major geographies analyzed under this research report are: 

  • Europe
  • North America 
  • Asia-Pacific 
  • Rest of the World 

This report gives you access to decisive data such as:

  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for the coming years 

Key highlights of this report

  • Overview of key market forces propelling and restraining market growth 
  • Up-to-date analyses of market trends and technological improvements 
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors 
  • An array of graphics and SWOT analysis of major industry segments 
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis 
  • Offers a clear understanding of the competitive landscape and key product segments

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Human Reproductive Technologies Market